Sangamo Therapeutics, Inc (SGMOQ) stock
SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Sangamo Therapeutics cash
Cash and short-term investments held at the end of each period.
Sangamo Therapeutics's cash was $27.59M at Mar 31, 2026. For fiscal 2025 it was $20.95M, down 50.0% from the year before. Over ten years it grew -11.3% a year on average. The highest annual figure on record is $642.92M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.95M | -50.0% |
| FY2024 | Dec 31, 2024 | $41.92M | -48.2% |
| FY2023 | Dec 31, 2023 | $81.00M | -73.7% |
| FY2022 | Dec 31, 2022 | $307.50M | -18.7% |
| FY2021 | Dec 31, 2021 | $378.05M | -41.2% |
| FY2020 | Dec 31, 2020 | $642.92M | +76.6% |
| FY2019 | Dec 31, 2019 | $363.97M | -9.8% |
| FY2018 | Dec 31, 2018 | $403.63M | +63.5% |
| FY2017 | Dec 31, 2017 | $246.81M | +1018.8% |
| FY2016 | Dec 31, 2016 | $22.06M | -68.2% |
| FY2015 | Dec 31, 2015 | $69.48M | +1052.3% |
| FY2014 | Dec 31, 2014 | $6.03M | -93.5% |
| FY2013 | Dec 31, 2013 | $92.81M | +46.1% |
| FY2012 | Dec 31, 2012 | $63.55M | -24.5% |
| FY2011 | Dec 31, 2011 | $84.13M | +39.6% |
| FY2010 | Dec 31, 2010 | $60.29M | +184.9% |
| FY2009 | Dec 31, 2009 | $21.16M | +9.0% |
| FY2008 | Dec 31, 2008 | $19.41M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $27.59M | +9.6% |
| Q4 FY2025 | Dec 31, 2025 | $20.95M | -50.0% |
| Q3 FY2025 | Sep 30, 2025 | $29.62M | -24.5% |
| Q2 FY2025 | Jun 30, 2025 | $38.34M | +38.0% |
| Q1 FY2025 | Mar 31, 2025 | $25.18M | -53.7% |
| Q4 FY2024 | Dec 31, 2024 | $41.92M | -48.2% |
| Q3 FY2024 | Sep 30, 2024 | $39.20M | -70.3% |
| Q2 FY2024 | Jun 30, 2024 | $27.79M | -84.7% |
| Q1 FY2024 | Mar 31, 2024 | $54.42M | -77.4% |
| Q4 FY2023 | Dec 31, 2023 | $81.00M | -73.7% |
| Q3 FY2023 | Sep 30, 2023 | $132.10M | -57.9% |
| Q2 FY2023 | Jun 30, 2023 | $182.10M | -42.3% |
| Q1 FY2023 | Mar 31, 2023 | $241.00M | -24.2% |
| Q4 FY2022 | Dec 31, 2022 | $307.50M | -18.7% |
| Q3 FY2022 | Sep 30, 2022 | $313.57M | -25.9% |
| Q2 FY2022 | Jun 30, 2022 | $315.72M | -40.4% |
| Q1 FY2022 | Mar 31, 2022 | $317.80M | -45.9% |
| Q4 FY2021 | Dec 31, 2021 | $378.05M | -41.2% |
| Q3 FY2021 | Sep 30, 2021 | $423.41M | -34.7% |
| Q2 FY2021 | Jun 30, 2021 | $529.65M | -20.3% |
| Q1 FY2021 | Mar 31, 2021 | $587.08M | +63.9% |
| Q4 FY2020 | Dec 31, 2020 | $642.92M | +76.6% |
| Q3 FY2020 | Sep 30, 2020 | $648.83M | +82.8% |
| Q2 FY2020 | Jun 30, 2020 | $664.85M | +50.7% |
| Q1 FY2020 | Mar 31, 2020 | $358.13M | +2.0% |
| Q4 FY2019 | Dec 31, 2019 | $363.97M | -9.8% |
| Q3 FY2019 | Sep 30, 2019 | $354.85M | -22.6% |
| Q2 FY2019 | Jun 30, 2019 | $441.10M | -18.2% |
| Q1 FY2019 | Mar 31, 2019 | $351.00M | +1043.0% |
| Q4 FY2018 | Dec 31, 2018 | $403.63M | +63.5% |
| Q3 FY2018 | Sep 30, 2018 | $458.57M | +1434.0% |
| Q2 FY2018 | Jun 30, 2018 | $539.45M | +672.4% |
| Q1 FY2018 | Mar 31, 2018 | $30.71M | +66.1% |
| Q4 FY2017 | Dec 31, 2017 | $246.81M | +1018.8% |
| Q3 FY2017 | Sep 30, 2017 | $29.89M | +6.8% |
| Q2 FY2017 | Jun 30, 2017 | $69.84M | +439.1% |
| Q1 FY2017 | Mar 31, 2017 | $18.49M | – |
| Q4 FY2016 | Dec 31, 2016 | $22.06M | – |
| Q3 FY2016 | Sep 30, 2016 | $27.99M | – |
| Q2 FY2016 | Jun 30, 2016 | $12.96M | – |
See a number that looks wrong?